INTRODUCTION:
The lipid kinase Vps34/ PIK3C3 phosphorylates phosphatidylinositol to yield phosphatidylinositol 3-phosphate (PI3P). Vps34 is important for processes that sort cargo to lysosomes, including phagocytosis, endocytic traffic, autophagy, and cytosol-to-vacuole transport. In mammalian cells, the enzyme also has roles in cytokinesis, signaling, recycling, and lysosomal tubulation.
Vps34 is present in multiple complexes. Complex I functions in autophagy and contains Vps34, Vps15 (p150/PIK3R4 in mammals), Vps30/Atg6 (Beclin 1), and Atg14 (ATG14L). Complex II takes part in endocytic sorting (as well as autophagy and cytokinesis in mammalian cells) and contains the same subunits as complex I, except that it has Vps38 (UVRAG) instead of Atg14. These complexes are differentially regulated in stress responses. In autophagy, PI3P emerges on small tubular or vesicular structures associated with nascent autophagosomes.
RATIONALE:
One of the most compelling questions is how the Vps34-containing complexes are organized and to what extent their intrinsic properties contribute to their differential activities in cells. To understand the mechanisms by which these complexes impart differential activities to Vps34, we sought to determine the structure of complex II and to characterize activities of Vps34 complexes on small and large vesicles. Because the complex resisted crystallization attempts, we screened 15 different nanobodies against the complex, and one of them enabled crystallization.
RESULTS:
We obtained a 4.4 Å crystal structure of yeast complex II. The structure has a Y-shaped organization with the Vps15 and Vps34 subunits intertwining in one arm so that the Vps15 kinase domain interacts with the lipid-binding region of the Vps34 kinase domain. The other arm has a parallel Vps30/Vps38 heterodimer. This indicates that the complex might assemble by Vps15/Vps34 associating with Vps30/Vps38. This assembly path is consistent with in vitro reconstitution of complex II and suggests how the abundance of various Vps34-containing complexes might be dynamically controlled. The Vps34 C2 domain is the keystone to the organization of the complexes, and several structural elaborations of the domain that facilitate its interaction with all complex II subunits are essential to the cellular role of Vps34.
We used hydrogen-deuterium exchange mass spectrometry (HDX-MS) to identify localized changes in all four complex II subunits upon membrane binding. We identified a loop in Vps30 (referred to as the "aromatic finger") that interacts directly with lipid membranes. Our assays showed that complexes I and II had similar activities on small vesicles (100 nm). In contrast, only complex II was active on giant unilamellar vesicles (GUVs) (2 to 20 mm). This activity was completely abolished by mutation of the aromatic finger.
CONCLUSION:
The structure, HDX-MS, and functional data allowed us to devise a model of how Vps34 complexes adapt to membranes. The tips of both arms of complex II work together on membranes. The Vps30 aromatic finger in one arm is important for the efficient catalytic activity of the other arm. The conformational changes that we detected may allow the arms to open to accommodate low-curvature membranes such as GUVs and endosomes.
Most of the interactions observed in the complex II structure are likely to be detected in complex I as well. The restriction of complex I activity in autophagy to membrane structures smaller than 100 nm may be related to the inactivity of complex I on GUVs in vitro. 1 
‡
Phosphatidylinositol 3-kinase Vps34 complexes regulate intracellular membrane trafficking in endocytic sorting, cytokinesis, and autophagy. We present the 4.4 angstrom crystal structure of the 385-kilodalton endosomal complex II (PIK3C3-CII), consisting of Vps34, Vps15 (p150), Vps30/Atg6 (Beclin 1), and Vps38 (UVRAG). The subunits form a Y-shaped complex, centered on the Vps34 C2 domain. Vps34 and Vps15 intertwine in one arm, where the Vps15 kinase domain engages the Vps34 activation loop to regulate its activity. Vps30 and Vps38 form the other arm that brackets the Vps15/Vps34 heterodimer, suggesting a path for complex assembly. We used hydrogen-deuterium exchange mass spectrometry (HDX-MS) to reveal conformational changes accompanying membrane binding and identify a Vps30 loop that is critical for the ability of complex II to phosphorylate giant liposomes on which complex I is inactive.
T he class III phosphatidylinositol 3-kinase (PI3K) known as Vps34 (vacuolar protein sorting 34, encoded by PIK3C3) is present in all eukaryotes. It phosphorylates phosphatidylinositol (PI) to yield phosphatidylinositol 3-phosphate (PI3P) (1), which is important for all vesicle-mediated sorting pathways to lysosomes, including processes such as phagocytosis, autophagy, multivesicular body formation, and cytoplasm-to-vacuole targeting. In yeast, PI3P production is totally dependent on Vps34 (2, 3), whereas in mouse embryonic fibroblasts, a VPS34 knockout suggests that 65% of PI3P derives from Vps34, with a class II PI3K producing the remainder (4). Vps34 forms complexes with other proteins (Fig. 1A ): Vps15 (encoded by PIK3R4, known as p150 in mammalian cells), Vps30 (encoded by VPS30/ATG6 in yeast, equivalent to mammalian Beclin 1, encoded by BECN1) and either Vps38 (UVRAG) or Atg14 (ATG14L). Atg14/ ATG14L defines complex I, involved in autophagy, which also includes Atg38 (5) as a fifth subunit (NRBF2 in mammalian cells), whereas Vps38 is characteristic of complex II and essential for vacuolar protein sorting (3) . In mammalian cells, complex II is also involved in autophagy, receptor degradation, and cytokinesis (6), as well as signaling (7, 8) , recycling (9) , and lysosomal tubulation (10) . Independently from complex I and II, Beclin 1 and UVRAG also play separate roles in endosome function and neuron viability (11) . Elevated expression of PIK3C3, PIK3R4, and BECN1 is associated with more aggressive forms of chronic lymphocytic leukemia (12), consistent with autophagy being involved in tumor maintenance. The crucial roles of complex I and complex II in stress response, nutrition, and disease have led to efforts to develop both activators and inhibitors, such as the recently developed adenosine triphosphate (ATP)-mimetic inhibitors of Vps34 kinase domain (7, 13, 14) .
Important questions concerning Vps34 complexes remain, such as the nature of the relationship between Vps15 and Vps34, the roles of Vps30 and Vps38/Atg14 in the functions of these complexes, and how the complexes recognize membranes. To address these questions and assist in the development of complex-specific drugs, we determined the crystal structure of complex II and characterized its dynamics and membrane binding.
The x-ray crystal structure of complex II Saccharomyces cerevisiae complex II displayed a 1:1:1:1 ratio of four subunits (Fig. 1B) . Crystallization required a nanobody (15) that recognized the Vps34 helical domain, as determined by hydrogen-deuterium exchange mass spectrometry (HDX-MS) [residues 386 to 406 ( fig. S1) ]. Using data from seven native crystals and phases from two Ta 6 Br 12 derivative crystals (table S1) , we produced a high-quality 4.4 Å resolution experimental electron density map (Fig. 1C) . Building the structure was challenging at this resolution. Initial models for several domains of the complex derived from previous structures and distant homologs (16) (17) (18) were fitted first, and the remainder of the structure was built directly into the density. The final model consists of 2834 residues out of the 3469 total, with most of the missing residues predicted to be disordered. Although side chains were not visible at this resolution, the sequence register was inferred from previously determined structures for most of Vps34, the WD40 domain of Vps15, and the C-terminal domain (CTD) of Vps30. An approximate sequence register was assigned for the remainder of the structure. The real-space correlation of the model with the density suggests that the fit is reasonable for most of the structure. The poorest fit to the density is in the Vps38 N-terminal C2 domain ( fig. S2 ).
Overall architecture of complex II
The complex has a Y shape, with two long arms and a short hook-like base (Fig. 1, D and E). The base is built entirely of the Vps30 and Vps38 Nterminal domains (NTDs) and coiled-coil 1 (CC1) domains. One of the arms (15 nm in length) consists of Vps15 and Vps34 (Fig. 1E) , whereas the other arm (18 nm) includes domains from all four subunits arranged along the Vps30 and Vps38 coiled-coil 2 (CC2). Vps30 and Vps38 show similar architectures except for their NTDs, where Vps38 has a C2 domain, whereas Vps30 is mostly unstructured (fig. S3, A and B) . At the C terminus, Vps30 has a BARA domain that binds side-by-side to the CTD of Vps38; we named this domain BARA2. The two arms of complex II correspond to the V shape seen in the lowresolution electron microscopy (EM) structure of complex I (19) . It is thus likely that most of the details seen in complex II are preserved in complex I.
Vps15/Vps34 catalytic heterodimer
Vps34 and Vps15 intertwine in an antiparallel fashion, with each of the three domains of Vps15 [kinase and helical (KINHEAT) and WD40] interacting with at least one domain of Vps34 [C2, as well as helical and kinase (HELCAT)] (Fig. 1D  and fig. S3 , C and D). This network of interactions explains the codependent relationship of the two proteins: Vps34 is essential for Vps15 integrity (3), whereas Vps15 is necessary for Vps34 membrane recruitment and activity in vivo (20) .
The N lobe of the Vps15 kinase domain lies at the tip of the right arm and interacts with the C lobe of the Vps34 kinase domain ( Fig. 2A) . It is not certain whether Vps15 is an active kinase or a pseudokinase. Wild-type (WT) Vps15 is phosphorylated, whereas kinase-dead variants are not, which suggests that Vps15 autophosphorylates (21) . Vps15 exhibits nontypical residues in critical catalytic elements: a 145-His-Gly-Asp sequence motif instead of His-Arg-Asp in the catalytic loop, a 165-AspPhe-Ala sequence motif instead of Asp-Phe-Gly in the activation segment, and the absence of a GxGxxG motif (G, Gly; x, any amino acid) (P loop) that normally binds phosphates in ATP (22) ( fig. S3C ). Although these substitutions are quite rare in the human kinome, they are found both in active kinases and pseudokinases (23) . The Vps15 kinase domain in our structure is probably in an inactive conformation because the long, partially ordered activation loop intrudes into the ATP binding site and would thus prevent ATP binding (Fig. 2B) .
The central part of Vps15 forms nine helical pairs wound into a right-handed helical solenoid stretching from the Vps15 kinase domain to the Vps38 CC1 and CC2 domains (Fig. 1D) . The first eight helical pairs are HEAT-type repeats. The helical solenoid has a concave face that nestles Vps34 C2. The Vps15 solenoid is followed by four more helices in a bundle (residues 788 to 885) capping the hydrophobic end of the solenoid. Most of the Vps15 linker between the solenoid and WD40 is disordered (residues 889 to 985), except for an extended section (residues 986 to 1050) threading along the surface of Vps34 C2.
The CTD of Vps15 is a seven-bladed WD40 domain (16) that bridges the Vps15/Vps34 and the Vps30/Vps38 pairs. On one side, conserved residues in the WD40 b3/b4 loop of blade 4 (1261-Arg-Phe, referred to as the RF loop) reach Vps34 C2, whereas on the other side, the only two other invariant residues, Glu 1077 and Ser
1121
(which are located between blades 1 and 7), contact Vps38 BARA2. Finally, one surface of the WD40 domain straddles Vps30 CC2. Due to this interaction, the greatest HDX differences in WD40 between the heterotetramer and the Vps15/ Vps34 heterodimer are for peptides in blades six and seven, which contact Vps30 CC2 (Fig. 2C) . Several Beclin 1 phosphorylation sites map to this CC2/WD40 interface ( fig. S4 ), where they could affect assembly of the active heterotetramer. The region of Vps30 in contact with the WD40 domain coincides with a region in mammalian Beclin 1 that is referred to as the evolutionarily conserved domain (ECD) (24) . Instead of binding Vps34 directly as previously proposed (24) , ECD binds to Vps15 WD40 and, therefore, only indirectly to Vps34.
Vps15 as a potential regulator of Vps34
Several catalytically important elements of Vps34 contact the kinase domain of Vps15: the activation loop (residues 749 to 767), helix ka10, and the ka11/ka12 elbow (residues 860 to 864) ( Fig. 2A) . These interactions are consistent with the observation that deletions in the ka11/ka12 region prevented association between Vps34 and Vps15 (25) . In protein kinases, the dynamics of the activation loop regulates catalytic efficiency (26) . Vps15 Helical conformation of the Vps34 lipid-binding site, including the activation loop. SUMOylation of residue Lys 840 in helix ka10 of hsVPS34 increases kinase activity (27) . This modification could regulate both the conformation of the Vps34 activation loop and its interaction with Vps15.
Vps15 could influence Vps34 in multiple ways: stabilizing the enzyme, inhibiting basal activity by restricting the activation loop, and contributing to membrane recruitment. The roles of Vps15 would be akin to the multiple roles of regulatory subunits of class IA PI3Ks. Oncogenic mutations of class I PI3Ks unmask the inhibitory role of the regulatory subunit (28) . In a human metastatic melanoma, a Vps15 Arg 107 →Gln 107 mutation in the kinase domain (29) is in close proximity to the C2/HELCAT linker helix and could affect Vps34 activity by reorientating the Vps15/Vps34 kinase domains.
VPS34 C2 domain as a hub for complex II formation
Although each Vps34 domain interacts with Vps15, the most extensive contacts involve Vps34 C2, which rests between the arms of the Y, engaging all subunits (Fig. 3A ). This domain was crucial for the function of Vps34 in cells ( Fig. 3B ) and important for tight association with Vps15 ( fig. S5 ). C2 domains often serve as membrane interaction modules; however, given the dense protein-protein interaction network centered on Vps34 C2, this domain is unlikely to also bind membranes.
The relationship of Vps34 C2 to Vps34 HELCAT is completely different than what has been observed for class I PI3Ks. The C2 domain of class I PI3Ks interacts extensively with the helical domain, whereas Vps34 C2 is remote from the rest of the enzyme, cradled by Vps15 HEAT (Fig. 3 , C and D). This relationship of Vps34 C2 to the Vps34 HELCAT may imply substantial flexibility around the linker between these two regions of Vps34, as suggested by a relatively high rate of global HDX ( fig. S6 ). Long-range motions of Vps34 HELCAT have been observed in the EM study of mammalian complexes I and II (19) . In our structure, most of the C2/HELCAT linker appeared disordered. However, a conserved linker helix ( Fig. 3C ) nestles in a crook between the Vps15 and Vps34, where it could provide a pivot for Vps34-HELCAT motions.
In addition to a b-sandwich scaffold, Vps34 C2 deploys two distinct features to assist with its role as a nucleus for complex II. The extended loop between the b1 and b2 strands (CBR1) reaches the Vps30/Vps38 CC2 domain ( Fig. 3E) , analogous to the critical interaction of the equivalent loop in class I PI3K C2 domains with the iSH2 coiled coil of the p85 regulatory subunit (28) . This constitutes the only contact of Vps34 with the Vps30/ Vps38 unit and explains the previously reported binding of hsVPS34 C2 to a Beclin 1 region encompassing the CC2 domain (30) . Deletion of CBR1 resulted in a phenotype similar to that resulting from the deletion of VPS34 (Fig. 3B) , which suggests that this is an important interaction in the complex.
A helical hairpin insertion [C2 helical hairpin (C2HH)] in the b7/b8 loop reaches the RF loop in Vps15 WD40 (Fig. 3A) . The HDX rate for C2HH was lower in complex II than in the Vps15/ Vps34 dimer (Fig. 2C) , suggesting a stabilizing role for C2HH. Nevertheless, the global rate of exchange for C2HH was higher than for the rest of Vps34 C2, indicating flexibility ( fig. S6 ), which might be regulated by phosphorylations ( fig. S4 ). Several of these modifications affect the activity of mammalian VPS34 (31, 32) . Deletion of C2HH in yeast Vps34 resulted in a temperature-sensitive phenotype (Fig. 3B) .
Organization of the Vps30/Vps38 pair
Vps30 and Vps38 interact along their entire lengths, forming an elongated structure that fits like a bracket around the Vps15/Vps34 heterodimer, along which Vps38 and, to a smaller extent, Vps30 establish multiple contacts with Vps15/Vps34. The two central coiled coils (a short CC1 and a longer CC2) of Vps30/Vps38 form a parallel heterodimer. Based on a low-resolution EM model (19) , a parallel arrangement of these two proteins was also proposed for the mammalian complexes I and II, whereas the homodimeric CC2 domain of Beclin 1 forms an antiparallel homodimer (33) . The bracket-like organization of the Vps30/ Vps38 pair relative to Vps15/Vps34 suggests that the complex might assemble from these two pairs. This is supported by a pulldown experiment showing that a purified Vps30/Vps38 heterodimer can capture purified Vps15/Vps34 ( fig. S7 ).
The C-terminal Vps30 BARA and Vps38 BARA2 domains are at the tip of the left arm, with Vps30 BARA interacting exclusively with Vps38 and Vps38 BARA2 contacting both Vps30 and Vps15 WD40. Vps30 BARA in complex II agrees closely with the structure of the isolated BARA (17, 34) (Fig. 4A) . Whereas Vps30 BARA has three b-a repeats, Vps38 BARA2 has two incomplete BARAtype repeats. The first repeat includes a helix preceded by an extended structure but not forming a clear b sheet, whereas the second repeat is complete (Fig. 4B) .
The most conserved part of Vps30 BARA forms an extensive interface with Vps38 BARA2, which is consistent with HDX data [the Vps30 peptide spanning residues 385 to 389 at the BARA/BARA2 interface being more protected in complex II than in free Vps30 (Fig. 4A)] . The Vps30 NTD, CC1, and CC2 also contribute to interaction with Vps38. In fact, the NTD, C2, and CC1 domains of Vps30 and Vps38 are sufficient to form a stable heterodimer in solution (Fig. 4C) .
The NTDs of Vps30 and Vps38 meet at the base of the complex, where they interact primarily with Vps15. The Vps30 NTD is not well defined, but we could build three disconnected helices that may be part of this domain (Fig. 5A) . In our interpretation, one of these helices forms a triple-helical bundle with CC1 of Vps38/Vps30. Furthermore, the density assigned to the Vps30 NTD is adjacent to Vps38 C2. This close spatial relationship is supported by our HDX-MS findings that identified a single nanobody binding to both Vps38 C2 (residues 45 to 55) and Vps30 NTD (residues 63 to 76). The HDX-MS results suggested additional contacts (not apparent at this resolution) between these domains, based on the large protection of the peptide spanning residues 82 to 86 in the Vps30 NTD in complex II versus Vps30 alone (table S2A).
Given that Vps38 defines complex II and is essential for vacuolar protein sorting (17), we used a carboxypeptidase Y (CPY) sorting assay in a vps38D mutant to characterize the role of Vps38 C2 and BARA2 (Fig. 5B) . DBARA2 showed only a partial rescue of CPY sorting, whereas DC2 did not rescue CPY sorting due to Vps38 degradation (Fig. 5C) . Thus, Vps38 BARA2 is important for vacuolar protein sorting, and Vps38 C2 is essential for the stability of Vps38 and, consequently, for complex II formation.
Implications for complex I
In complex I, Vps38/UVRAG is substituted with Atg14/ATG14L. Although the NTDs of Vps30, Vps38, and Atg14 differ, the overall similarity of their domain organizations suggests that these proteins may have evolved from a common ancestor. The lengths of the Atg14 and Vps38 coiledcoil regions are comparable, which suggests that Atg14 probably interacts similarly with the CC1 and CC2 domains of Vps30 as compared to its interaction with Vps38.
The C-terminal extension of human Atg14L contains a BATS domain previously shown to interact with membranes. In our model, the BATS domain would share proximity with other elements of the complex involved in membrane binding (see next section). In yeast, the amphiphilic helix at the C terminus of Atg14 (residues 240 to 261) could act as its functional counterpart. The absence of a C2 domain in Atg14 to interact with the Vps30 NTD may explain why the Vps30 NTD is dispensable for autophagy, in contrast to the critical role of the Vps30-CTD (17) .
Membrane interactions of complex II
Because the activity of all PI3Ks is controlled by their association with membranes, we examined this interaction for intact complex II. Comparing HDX for complex II in the presence and absence of membranes showed that localized changes in exchange for all four subunits accompany membrane binding (Fig. 6A and table S3 ). Vps30 BARA (residues 424 to 443) shows a decreased rate of HDX, suggesting that this region directly interacts with membranes, consistent with Vps30 BARA greatly contributing to endosomal localization of complex II (17) . The analogous region (359-Phe-Phe-Trp) in Beclin 1 BARA contains the membrane-binding aromatic finger (34) . For simplicity, we also will refer to Vps30 residues 430-Phe-Arg-Lys-432 as the aromatic finger ( fig. S3A) . Two known membrane-binding elements in Vps34, the activation loop and the C-terminal ka12 helix, did not display a decrease in HDX rate. An increased rate of HDX in the Vps34 activation loop likely reflects a disruption of the contact between this loop and the N terminus of Vps15 enabling the activation loop to bind lipids, whereas contacts made by the ka12 helix in the closed conformation observed in complex II are replaced by membrane interactions (18) . Thus, the net HDX rate that we observe for the Vps34 kinase domain upon membrane binding is presumably a sum of increases in HDX due to conformational changes and decreases associated with direct membrane interaction.
In our model for Vps34 complexes on membranes (Fig. 6A) , the tips of the two arms contact the membrane: one arm via the Vps34 activation loop, the Vps34 ka12 helix, and the Vps15 Nterminal myristoylation site, and the other arm via the Vps30/Beclin 1 BARA domain. Both Vps15 WD40 and Vps34 interact with the yeast lipidated Ga subunit Gpa1 on endosomes (35) , and VPS34 interacts with Gai at the midbody (36) . It is plausible that membrane-localized Gpa1 would fit into the notch between the two arms of complex II. Mammalian VPS34 complexes are regulated by Rab5 (37) and Rab7 (38) , and these G proteins may occupy the same crevice between the two arms of the complexes.
Activity of Vps34 complexes on small and large vesicles
To evaluate the influence of the Vps30-containing arm on Vps34 activity, we compared activities of complex I, complex II, and the Vps15/Vps34 heterodimer on small and large vesicles. On small unilamellar vesicles (SUVs), complexes I and II had similar activities that are higher than that of the heterodimer (Fig. 6B ). Complex II with a mutation in the Vps30 aromatic finger (430-Phe-ArgLys-432 mutated to Asp-Asp-Asp) showed lower activity, similar to that of the Vps15/Vps34 dimer (Fig. 6B) . Notably, complexes I and II differed substantially in their activities on giant unilamellar vesicles (GUVs). Complex I and the Vps15/Vps34 heterodimer were inactive on GUVs, whereas complex II efficiently phosphorylated these relatively low-curvature membranes (Fig.  6C ). This ability depended critically on the Vps30 aromatic finger, because the Phe-Arg-Lys/AspAsp-Asp mutant had an activity indistinguishable from that of Vps15/Vps34. It is noteworthy that a cluster of posttranslational modifications maps to loops in the Vps30 BARA domain (fig. S4 ). These inhibitory modifications may prevent the aromatic finger from interacting with membranes. Atg14 might block the basal membrane-binding ability of Vps30 in complex I on GUVs; in cells, this block could be relieved by starvation.
Membrane binding was accompanied by exposure of peptides in both the arms and base of the complex (Fig. 6A) , indicating conformational changes compatible with global opening and closing motions such as those suggested by a normal mode analysis (movie S1). These data allow us to devise a model for how complex II adapts to membranes (Fig. 6D) . Conformational shifts in the base would enable opening of the arms to adjust to different membrane curvatures. Flexing joints at the junction between Vps30 CC2 and Vps30 BARA and between the Vps15/Vps34 kinase domains would then enhance productive membrane binding. In contrast to complex II, which operates on relatively flat endosomal membranes, complex I is associated with highly curved membranes. Accordingly, human ATG14L has a C-terminal BATS domain that senses membrane curvature (39) . Highly curved membranes could more readily fit into the notch between the two arms (Fig. 6E) . PI3P recognition and curvature sensitivity conferred by the BATS domain could set up a positive-feedback loop for rapid, localized buildup of PI3P on highly curved membranes, such as the tubular or vesicular structures associated with the tips of the autophagic isolation membrane (40) originating at the omegasome (41) . The Y-shaped complexes I and II constitute bipartite structures with catalytic activity in the Vps15/Vps34 arm and functional specificity arising from the Vps30/Vps38 (or Vps30/Atg14) arm and base. These assemblies constitute recruitment platforms for regulatory proteins and downstream factors, fine-tuning Vps34 activity. This detailed view of the whole complex provides a framework for designing selective activators and inhibitors of Vps34 complexes targeting not only the active site but also complex-specific membrane-and protein-binding interfaces. The structure should enable a better understanding of the regulation of Vps34 autophagic and endosomal complexes by posttranslational modifications, binding partners, and membranes.
Materials and methods Constructs
All DNA constructs used in this study are listed in table S5.
Yeast strains and cell growth
Yeast strains used in this study are listed in table S6. Cell growth for protein expression is described in the below sections on protein purification. For cell biology, yeast cells carrying plasmids were grown at 30°C in medium lacking uracil (-URA) (0.67% yeast nitrogen base without amino acids; 0.5% casamino acids and 2% glucose, supplemented with 0.002% adenine sulfate; 0.002% tryptophan; 0.002% tyrosine; and 0.002% leucine).
Protein purification: Complex II
Plasmids carrying genes encoding S. cerevisiae PI3K complex II subunits were transformed into BCY123 or YOY193 yeast cells (see tables S5 and S6 for details). All coding fragments were under the GAL1 promoter (Somatogen). Cells were grown in YM4 medium (0.67% yeast nitrogen base without amino acids; 0.5% casamino acids and 2% glucose, supplemented with 0.002% adenine sulfate; and 0.002% tyrosine) for double-plasmid expression using pRS424-and pRS426-backbone plasmids or in -URA medium for pRS426-backbone plasmids. Flasks containing a total of 10 liters of cells were grown at 30°C in the presence of 2% galactose for 24 hours. Cells were lysed in lysis buffer [50 mM Tris at pH 8.8, 300 mM NaCl, 1 mM dithiothreitol (DTT), 1% Triton-X, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and a protease inhibitor tablet (Roche 05056489001) with glass beads (Sigma G8772)] using a cell disruptor (FastPrep-24, MP Biomedicals). Immunoglobulin G (IgG) beads (GE Healthcare 17096902) were added to the lysate, incubated for 3 hours at 4°C, and then washed once with wash 1 buffer (50 mM Tris at pH 8.0, 300 mM NaCl, 1 mM DTT, 1% Triton-X, and 0.5 mM PMSF) and once with wash 2 buffer (50 mM Tris at pH 8.0, 300 mM NaCl, 1 mM DTT, and 0.5 mM PMSF). The protein A (ZZ) tags were cleaved by TEV protease in wash 2 buffer overnight. The elution fractions were concentrated and subjected to gel filtration on Superdex 200 16/60 equilibrated in 20 mM Tris at pH 8.0, 300 mM NaCl, and 1 mM tris(2-carboxyethyl)phosphine (TCEP). The aromatic finger mutant complex II (with Vps30 residues 430-Phe-Arg-Lys-432 mutated to AspAsp-Asp) was purified in the same way as the WT complex II.
Protein purification: Complex I
The S. cerevisiae complex I was expressed as described above. The protocol for complex I purification was essentially the same as for complex II, with three differences: (i) 150 mM NaCl was used in all buffers, (ii) 0.5% CHAPS was used as a detergent, and (iii) a solution containing 20 mM Tris at pH 8.8, 150 mM NaCl, and 1 mM TCEP was used for gel filtration.
Protein purification: Vps15/Vps34 dimer The S. cerevisiae Vps15/Vps34 heterodimer was expressed as described above. The purification protocol was the same as for complex II, with some differences: Wash 1 and wash 2 buffers contained 500 mM NaCl. Once the protein A tags were cleaved off with TEV protease overnight, the sample was diluted with three volumes of HEP-A buffer (20 
Production of nanobodies
Nanobodies were generated against cross-linked complex II. Protein for generating nanobodies was produced from 10 liters of yeast cell culture.
Complex II was purified as described above, except that the wash 2 buffer was composed of 50 mM HEPES at pH 7.4, 300 mM NaCl, 1 mM TCEP, and 0.5 mM PMSF. Proteins on IgG beads were incubated overnight with TEV protease in 10 ml of wash 2 buffer at 4°C. After the first elution, 5 ml of wash 2 buffer without TEV protease was added and a second elution was performed. The two TEV elution fractions were combined, and CHAPS was added to a concentration of 0.1%. Protein was concentrated for gel filtration (Amicon Ultra 100-kD cutoff, Millipore). Gel filtration was carried out on a Superdex 200 16/60 column (GE Healthcare), which was pre-equilibrated with gel-filtration buffer (20 mM HEPES at pH 7.4, 300 mM NaCl, and 1 mM TCEP). The peak fractions were combined and concentrated to 400 ml at 6.3 mg/ml (16 mM). The whole amount was used for the cross-linking. Complex II at 10 mM was cross-linked using a CovalX K200 stabilization kit (CovalX, Zurich, Switzerland) by following the manufacture's protocol. After removing precipitates by centrifugation, the cross-linked material was frozen in liquid nitrogen and shipped on dry ice to the Steyaert laboratory for immunization.
Complex II-specific nanobodies were generated following the previously described protocol (15) with 100 mg of cross-linked complex II. Peripheral blood lymphocytes were extracted 4 days after the final antigen boost. RNA was purified and converted into cDNA via reverse transcriptase polymerase chain reaction (PCR). The cDNA was cloned into phage display vector pMESy4 containing a C-terminal 6X His tag. For the phage selection, complex II (both cross-linked and native) was directly coated on the solid phase. Antigenbound phages were recovered by proteolysis with trypsin. After selections, 53 clones were sequenced, of which 38 tested positive in an enzyme-linked immunosorbent assay (ELISA). Nanobody 8780, which was crystallized with complex II for structure determination, was selected using non-cross-linked material.
Expression and purification of nanobodies for crystallization WK6 Su -cells were transformed with the plasmids carrying VHH constructs genes from the selections described above. Cells were grown at 37°C to optical density at 600 nm = 0.7 and then induced with 1 M isopropyl-b-D-thiogalactopyranoside for 20 hours at 25°C. For the initial screening, 1 liter of cell culture was grown for each nanobody. For further characterization and crystallization trials, 6 liters of cell culture were grown. Nanobodies were purified from the cell periplasm. Cells from 1 liter of culture were resuspended on ice with 15 ml of TES buffer (200 mM Tris-HCl at pH 8, 0.5 mM EDTA, and 500 mM sucrose) and then rotated for 1 hour at 4°C. After incubation, 30 ml of 4× diluted TES buffer (50 mM Tris-HCl at pH 8, 0.125 mM EDTA, and 125 mM sucrose) buffer was added to the cells, followed by further rotation for 45 min at 4°C. After ultracentrifugation, the supernatant was loaded onto Ni/NTA beads (Qiagen) equilibrated in wash buffer (50 mM phosphate at pH 7, 1 M NaCl) and washed extensively in the same buffer, followed by washing with a low-imidazole solution (50 mM phosphate at pH 7.4, 1 M NaCl, and 15 mM imidazole at pH 8). The protein was eluted with 200 mM imidazole at pH 8, 20 mM phosphate at pH 7.4, and 1 M NaCl and then concentrated in Amicon Ultra 5-kD cut-off concentrator before being loaded on a S75 10/30 gel filtration column (for small-scale 1-liter expression) or a S75 16/60 column (for large-scale 6-liter expression) equilibrated in 20 mM Tris-HCl at pH 7.5 and 150 mM NaCl.
Crystallization
Purified complex II was mixed with an excess of a purified nanobody, and the mixture was gelfiltered on a 16/60 Superdex 200 column. The relevant fractions were pooled; concentrated to between 6 and 7 mg/ml; and screened for crystallization in more than 1900 conditions using the LMB robotic crystallization setup (42) , with 100 nl of protein and 100 nl of the reservoir solution in 96-well plates. Initial crystals of complex II were obtained using Crystal Screen 1 reagent 3 (Hampton Research), which contains 0.4 M monoammonium dihydrogen phosphate. The crystals were optimized in grids varying the concentration of reagents; adjusting pH; and screening different salts, cryogenic protectants, detergents, and other additives. For data collection, crystals were produced in 96-well plates, using 200 nl of protein and 200 nl of the reservoir solution containing 0.35 M sodium acetate and 3% 1,5-diaminopentanedihydrochloride. Crystals were grown at 17°C and reached the maximum size after 5 to 7 days. Crystals were cryo-protected by adding to the drop a solution containing 0.35 M sodium acetate, 3% 1,5-diaminopentanedihydrochloride, and 25% ethylene glycol. Crystals were mounted in loops and flash-cooled in liquid nitrogen.
Structure solution
Diffraction data were collected at the European Synchrotron Radiation Facility on beamline ID29 and at the Diamond Light Source on beamlines I04 and I24. Native crystals of complex II bound to a nanobody diffracted to~4.4 Å resolution; some of these were soaked for 1 to 10 min in 2 mM tantalum bromide (Jena Biosciences PK-103) dissolved in the crystallization solution. We optimized data collection for tantalum-derivatized crystals by estimating the total dose absorbed using RADDOSE (43) . Data sets for tantalum-soaked crystals were collected at the peak absorption edge and at the two different inflection points for this element (see table S1 ). Data were processed with XDS and scaled using XSCALE (44) . Experimental phasing was carried out using either Sharp or Autosharp (45) . The signal over noise for native crystals could be enhanced by combining seven isomorphous data sets together with XSCALE, which would allow us to adopt a 4.4 Å resolution cutoff. A list of initial sites was obtained using SHELX C/D (46), enabling us to obtain a first experimental map in which previously solved models of the WD40 domain of Vps15, the BARA domain, coiled-coil domains of Vps30/38, and the HELCAT domain of Vps34 could be readily placed. At this stage, the electron density was clear enough to build most of the helices of the helical domain of Vps15. Missing parts of the complex, such as the kinase domain of VPS15 and the C2 domains of Vps34 and Vps38, were subsequently found using homemade scripts for serial molecular replacement with PHASER (47), with model libraries obtained from HHPRED secondary-structure profile matching hits (48) or BALBES (49) . Improvement of the initial model was possible by successive rounds of model building and refinement, followed by density modification with SOLOMON (50) from the SHARP server interface using the updated model every time as a solvent mask to generate a better experimental map. Refinement was performed using tight secondary structure and Ramachandran restraints with PHENIX (51). Given the low resolution, no side chains were incorporated; however, the model contains the yeast sequence register.
HDX sample preparation: Dynamics and protein contacts
HDX-MS experiments were conducted to determine the complex dynamics and protein contacts within the complex. The D 2 O used in all experiments had ≥99.75% isotopic purity (Acros Organics). Protein samples [10 ml of 2.5 mM protein in dilution buffer (20 mM Tris at pH 8.0, 50 mM NaCl, and 2 mM TCEP)] were mixed rapidly with 35 ml of D 2 O buffer (20 mM Tris at pH 8.0, 50 mM NaCl, 2 mM TCEP, and 96.6% D 2 O) to produce a sample with a final concentration of 75% D 2 O. Four time points of exchange (3 s on ice; 3 s, 30 s, and 300 s at 23°C) were produced in triplicate. For each time point, the reaction was quenched by the addition of 20 ml of quench buffer (8.4% formic acid and 5 M guanidine-HCl) and immediate freezing in liquid nitrogen. Samples were then stored at -80°C.
HDX sample preparation: Nanobody mapping
For nanobody-binding experiments, 10 ml of either 2.5 mM complex II or 10 ml of a 2.5 mM complex II/ 3 mM nanobody solution were mixed rapidly with 40 ml of D 2 O buffer (producing a final concentration of 77% D 2 O). Reactions were incubated for 3 s on ice before being quenched with 20 ml of quench buffer and frozen in liquid nitrogen as described above.
HDX sample preparation: Membrane binding
Membrane-binding experiments were carried out using liposomes produced as described previously (28) . Briefly, phospholipids were mixed in organic solution in the desired ratios {18% (w/v) liver phosphatidylinositol (Avanti 840042C), 45% brain phosphatidylserine (Avanti 840032C), 20% brain phosphatidylethanolamine (Avanti 840022C), and 17% brain phosphatidylcholine (Avanti 840053C) [grossly mimicking yeast plasma membrane, partly modified from (52)]}, desiccated, resuspended in lipid buffer (20 mM Tris at pH 8.0, 100 mM KCl, and 1 mM EGTA), sonicated, freeze-thawed 10 times, and then extruded 11 times through a 100-nm filter. For HDX-MS experiments, complex II (2.5 mM final concentration) was incubated with either 1 mg/ml of liposomes or the equivalent volume of lipid buffer for 30 min before the addition of any deuterated buffer. HDX reactions were then conducted as described above, with 10 ml of protein or protein-lipid solution being mixed with 40 ml of D 2 O buffer supplemented with either 1 mg/ml of liposomes or the equivalent volume of lipid buffer (76.6% D 2 O). The final concentration of D 2 O was 61%. Four incubations were conducted (3 s on ice; 3, 30, and 300 s at 23°C), and the samples were quenched and stored as noted above.
Measurement of deuterium incorporation
All samples were analyzed using the same chromatography system and mass spectrometry instruments. Protein samples were thawed and immediately injected into an ice-immersed ultra performance liquid chromatography (UPLC) system. The protein was initially passed through two immobilized pepsin columns (Applied Biosystems; poroszyme) at 150 ml/min for 3 min to digest the protein, and the resulting deuterated peptides were collected on a VanGuard precolumn trap (Waters). The trap was then switched in-line to an Acquity 1.7-mm particle, 100-mm-by-1-mm C18 UPLC column (Waters), and the peptides were eluted from the column using a 20-min 5 to 45% gradient of buffer A (0.1% formic acid) and buffer B (100% acetronitrile), followed by a 4-min 76% buffer B wash. The mass of the eluted peptides was then determined using a Xevo quadrupole-time-of-flight mass spectrometer (Waters), acquiring for 30 min over mass/charge ratios of 350 to 1500, using an electrospray ionization source operated at a capillary temperature of 225°C and a spray voltage of 3.5 kV.
Peptide identification
The identification of nondeuterated peptides was determined by running tandem mass spectrometry (MS/MS) experiments with a nondeuterated sample digested as noted above but with a 60-min gradient over the reverse-phase column. This was repeated with a 20-min gradient, and identical peptides observed in both gradients were used to produce a linear extrapolation to correct for the retention times of peptides observed in the 60-min gradient. A tolerance of 15 parts per million was used in the MS observations, and an MS/MS tolerance of 0.2 daltons was also used. The resultant MS/MS data sets were analyzed using Mascot Distiller (Matrix Science). Peptides with a Mascot score lower than 10 were excluded from all further analysis. Centroid values were determined using HD-Examiner software (Sierra Analytics). Every nondeuterated peptide was validated manually by searching the protein sample's MS scan and checking for the correct charge state, the presence of any overlapping peptide envelopes, and a correct retention time (peptides failing any of these criteria were excluded from further analysis). Peptide coverage was as follows: Vps38, 51.9%; Vps34, 83.6%; Vps30, 82.9%; and Vps15, 36.8%.
Mass analysis of peptide centroids
Validated nondeuterated peptides were subsequently analyzed for their deuterium incorporation under various conditions. Due to overlap from the shift in isotopic envelope observed upon deuterium incorporation, additional peptides were discarded from the data set. All peptides were again checked for the correct charge state and retention time. All deuterium levels quoted in the figures and text are relative levels of deuterium, as no fully deuterated sample was obtained. A mathematical correction was applied using HD Examiner to compensate for the differences in the level of the deuterium in the various D 2 O buffers. The average error was ≤0.5 daltons for any two replicates. Changes greater than 0.9 daltons for both observations were tested for significance with a Student's t test at the 95% confidence level. All results quoted in the figures and text are the greatest observed difference for that peptide at any single time point, unless otherwise explicitly stated.
CPY assay
Our CPY assay was modified from (17) . Cells were grown at 30°C to mid-log phase [absorbance at 600 nm (A 600 ) = 0.8 to 1.0] in -URA medium, and an equivalent of five absorbance units of cells was collected and resupended in 500 ml of -URA medium with 50 mM KPO 4 at pH 5.7 and 0.5 mg/ml bovine serum albumin (BSA) and incubated at 30°C for 1 hour. Cells and extracellular fractions were separated by centrifugation at 4000g for 1 min. Cellular fractions were subjected to the cell wall-loosening procedure (2 M LiAc on ice for 2 min, followed by 0.4 M NaOH on ice for 2 min), resuspended in a solution of 50 mM Tris at pH 8.0, 1% SDS, 8 M urea, 2 mM DTT, and 5 mM EDTA with glass beads, and disrupted at 3000 revolutions per minute (rpm) for 30 s with PowerLyzer (Mo Bio) at 4°C. One part of 4× sample buffer was added to 3 parts of lysate and loaded on gel without boiling. Extracellular fractions were precipitated with final 10% trichloroacetic acid (from 100% stock) on ice for 30 min and centrifuged at 20,000g for 10 min. Pellets were washed two times with 90% cold acetone, air-dried, resuspended in 2× sample buffer, and loaded on gel without boiling. CPY is synthesized as a premature form (p1), transported to the Golgi to be glycosylated (p2), and then delivered to the vacuole, where it is cleaved to a mature form (m). The p2 and m forms of CPY were detected both in cellular and medium fractions using anti-CPY (1/200; Invitrogen A6428). Vps38 proteins, which were all C-terminally tagged with 3× Flag, were detected by anti-Flag-HRP (HRP, horseradish peroxidase) (1/1000; Sigma A8592). Both full-length Vps38 and DBARA2 show two protein bands. The bands with higher molecular weight correspond to the sizes of interest (asterisks in Fig. 5B ). Pgk1 was detected by anti-Pgk1 (1/2000; Invitrogen 459250). Anti-mouse-HRP (1/2000; Sigma A9917) was used as a secondary antibody.
Protein A pull-down assay
Plasmids carrying VPS15-ZZ (pYO225) were cotransformed with an empty vector (pRS424), untagged VPS34 (pYO69), or HELCAT (pYO361) into a yeast strain (YOY193). Protein expression was induced by 2% galactose for 24 hours at 30°C in 500 ml of YM4 medium in the presence of 2% glycerol and 3% lactic acid. Cells were harvested in 50-ml tubes, then 5 ml of lysis buffer (50 mM Tris at pH 8.8, 300 mM NaCl, 1 mM DTT, 1% triton, 0.5 mM PMSF, and an inhibitor tablet) and 3 g of glass beads were added. Cells were disrupted once with FastPrep-24 at 6.5 intensity for 45 s. Cell debris and glass beads were removed by centrifuging at 4000 rpm for 2 min. Supernatants were transferred to ultracentrifuge tubes and spun at 20,000g for 10 min. IgG beads (100 ml of 50% slurry) were added to supernatants and rotated at 4°C for 2 hours. The protein-bound beads were transferred to Poly-Prep chromatography columns (Bio-Rad) and washed with 10 ml of wash buffer (50 mM Tris at pH 8.0, 300 mM NaCl, 1 mM DTT, 1% Triton X-100, and 0.5 mM PMSF) and 10 ml of wash 2 buffer (50 mM Tris at pH 8.0, 300 mM NaCl, and 1 mM DTT) by gravity flow. After draining the wash 2 buffer, IgG beads were resuspended in 500 ml of wash 2 buffer. A fraction of lysate (0.04%) and beads (2%) were loaded on a gel.
Microscopy
Cells were grown to mid-log phase (A 600 = 0.8 to 1.0) and then examined with an inverted microscope (Nikon Eclipse TE2000) equipped with a charge-coupled device camera (CoolSNAP-HQ2, Roper Scientific, Tucson, AZ), a green fluorescent protein (GFP) filter (Chroma Technology, Rockingham, UT), and a differential interference contrast channel. Images were analyzed using ImageJ, and levels were adjusted with Adobe Photoshop.
Vps15/Vps34-Vps30/Vps38 reconstitution A yeast plasmid carrying VPS30 and ZZ-VPS38 (pYO734) was transformed into the YOY193 strain. The transformed cells were grown overnight at 30°C in -URA medium and then shifted to 1 liter of induction medium (YM4, 2% glycerol, 3% lactic acid, 2% galactose, 5 mM ZnCl 2 , 55 mg/liter leucine, and 55 mg/liter tryptophan) at 30°C for 24 hours. Cells (~10 g) were obtained and split into two aliquots of 5 g in 50-ml tubes. Cells per tube were disrupted in 5 ml of lysis buffer (50 mM Tris at pH 8.8, 150 mM NaCl, 1 mM DTT, 1% Triton X-100, 0.5 mM PMSF, and an EDTA-free protease inhibitor tablet) and 3 g of glass beads using a FastPrep24 at 6.5 intensity for 45 s. Cell debris and glass beads were spun down at 2500g for 2 min. Supernatants were combined and spun at 20,000g for 10 min. IgG beads (100 ml) were added to the supernatant and rotated at 4°C for 2 hours. For the IgG beads-only control, 50 ml of IgG beads was added in 5 ml of lysis buffer and rotated as described above. The control and protein-bound IgG beads were transferred to Poly-Prep chromatography columns and washed with 10 ml of wash buffer (50 mM Tris at pH 8.0, 150 mM NaCl, 1 mM DTT, 1% Triton X-100, 5 mM ATP, 50 mM MgCl 2 , and 2 mg/ml ribonuclease A) and 10 ml of reaction buffer (50 mM Tris at pH 8.0, 300 mM NaCl, and 1 mM DTT) by gravity flow. The protein-bound IgG beads were split into two halves, one for the control without Vps15/Vps34 and the other for the reconstitution with Vps15/Vps34. After draining the buffer, 225 ml of reaction buffer was added to each column, and then 25 ml of purified Vps15/Vps34 was added to a final concentration of 1 mM. A binding reaction was performed on ice for 1 hour. Beads were washed once with 10 ml of wash 2 buffer (50 mM Tris at pH 8.0, 300 mM NaCl, 1 mM DTT, and 1% Triton X-100) and once with 10 ml of reaction buffer. 2.5% of total volume was loaded on a SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gel for input and IgG bead fractions.
Lipid kinase assays
Lipid kinase assays were carried out using liposomes produced as described above. Phospholipids were mixed in organic solution in the desired ratios [18% (w/v) phosphatidylinositol, 10% phosphatidylserine, 17% phosphatidylethanolamine, and 55% phosphatidylcholine], desiccated in a nitrogen stream, and then resuspended in lipid buffer (25 mM HEPES at pH 8.0, 100 mM NaCl, and 1 mM EGTA) to make a 1-mg/ml stock. The stock was sonicated in a bath sonicator, freezethawed 10 times, and then extruded 11 times through a 100-nm filter.
SCIENCE sciencemag.org Lipid kinase assays were performed using the Echelon K-3000 kit, a 96-well ELISA assay for detection of PI3P. Protein dilutions and lipid stocks were made in reaction buffer (25 mM Tris at pH 8.0, 150 mM NaCl, 2 mM EGTA, 0.1% CHAPS, 4 mM MnCl 2 , and 2 mM TCEP). First, 5 ml of 20 nM enzyme was aliquoted into PCR tubes. The reaction was initiated by adding 5 ml of liposomes in reaction buffer with 100 mM ATP to give a final enzyme concentration of 10 nM and a final PI concentration of 50 mM. Control reactions without ATP were also set up for all proteins. The reaction was incubated for 1 hour at room temperature without agitation, stopped by addition of 16.6 mM EDTA, and diluted to 80 ml in the 2× PI3P detection buffer (K-3004). Next, 50 ml of this reaction solution was transferred to the detection plate (K-3001). PI3P was then detected on a plate reader according to the manufacturer's instructions. A kinase-dead Vps34 (D731N) in the Vps34/Vps15 dimer was used as a negative control. Error bars in Fig. 6B represent SD from the mean for triplicate measurements. The results shown are representative of at least three independent experiments.
Giant unilamellar vesicle (GUV) assay
Two concentric greased O-rings (16 and 18 mm in diameter) were placed on the metal side of an indium tin oxide-coated glass slide. An aliquot (10 ml) of the 1-mg/ml lipid mixture of 18% (w/v) liver phosphatidylinositol, 10% brain phosphatidylserine, 17% brain phosphatidylethanolamine, 55% brain phosphatidylcholine (catalog numbers as above), and 0.1% Lisamine Rhodamine-PE (Avanti 810850P) was pipetted into the center of the rings and dried in a vacuum for 1 hour. Swelling buffer (500 mM glucose, 220 ml) was added to each ring. The slide was then placed into the Vesicle Prep Pro GUV generator (Nanion) and covered with another indium tin oxide-coated glass slide. An ac field (1 V, 10 Hz) was applied to the slides for 4 hours at 60°C. The wells of the observation chamber (Lab Tek chamber 1, Borosilicate, 155411) were pre-equilibrated with 5 mg/ml of BSA for 4 hours and then washed with the observation buffer (50 mM HEPES at pH 8.0, 150 mM NaCl). GUVs (50 ml) were added to a solution with enzymes and a PI3P detection probe (p40PX domain labeled with AlexaFluor647) to yield a 200-ml solution of observation buffer supplemented with 1 mM EGTA, 2 mM MnCl2, 1 mM TCEP, and 50 mM ATP, with an enzyme concentration of 0.5 mM and a probe concentration of 7 mM. Confocal images were acquired using Zeiss LSM 780, with a ×63 (NA 1.4) oil objective lens.
Temperature-sensitivity experiment
The plasmids were transformed into SEY6210 (WT) or vps34D. After 2 days at 30°C on -URA plates, newly growing colonies were repatched onto new -URA plates and grown at 30°or 37°C for 2 days. Protein expression was also confirmed by Western blotting with anti-Flag-HRP.
